In this photo illustration, Tesla logo is seen displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Gary Black Expects Musk’s $1T Pay Package To Receive ‘Overwhelming’ Approval But Warns Against Optimism On Tesla Robotaxi Expansion Plans

 Black said in an X post on Monday that he expects the new compensation plan to receive 70% to 75% votes at Thursday’s annual meeting. 

Equity

<ul class="summary-bullets"><li>BitMine’s ETH assets alone account for about 2.8% of the total Ethereum supply.&nbsp;</li><li>The company’s combined crypto, cash, and “moonshot” assets now total an estimated $13.7 billion.</li><li>Bitcoin’s price moved 3% lower, and Ethereum’s price fell 7% in the last 24 hours.</li></ul>BitMine Immersion Technologies (BMNR) announced on Monday that its combined crypto, cash, and “moonshot” assets now total an estimated $13.7 billion, down from the $14.2 billion value as of October 27.The company focuses on building long-term crypto holdings, mainly in Bitcoin (BTC) and Ethereum (ETH). It acquires assets through its own mining operations and through the raising of capital.&nbsp;<h2 class="st-heading-2">Crypto Footprint</h2>As of November 2, the company’s portfolio included 3,395,422 ETH at $3,903 per ETH, 192 BTC, $62 million in Eightco Holdings Inc. (ORBS), and $389 million in unrestricted cash.&nbsp;The firm’s ETH assets alone account for about 2.8% of the total Ethereum supply. BitMine’s total crypto holdings place it second only to Strategy Inc. (MSTR), which owns roughly 640,000 BTC valued at over $70 billion.&nbsp;Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/BMNR">BitMine’s stock</a> traded 7% lower by mid-morning on Monday. The stock was also dragged down by a fall in both BTC and ETH prices.&nbsp;<a href="https://stocktwits.com/coins/bitcoin">Bitcoin’s price</a> moved 3% lower, and&nbsp;<a href="https://stocktwits.com/coins/ethereum">Ethereum’s price</a> fell 7% in the last 24 hours.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around BitMine Immersion stock remained in ‘bearish’ territory amid ‘normal’ message volume levels.&nbsp;<figure class="image"><img style="aspect-ratio:933/105;" src="https://news.stocktwits-cdn.com/Screenshot_2025_11_03_113506_png_455b45305f.webp" alt="BMNR’s Sentiment Meter and Message Volume as of 11:10 a.m. ET on Nov. 3, 2025 | Source: Stocktwits" width="933" height="105"><figcaption>BMNR’s Sentiment Meter and Message Volume as of 11:10 a.m. ET on Nov. 3, 2025 | Source: Stocktwits</figcaption></figure>A bearish Stocktwits user predicted that BMNR stock could reach $20 this week.<stembedurl>https://stocktwits.com/fatGuy320lbs/message/634704695</stembedurl>Another user highlighted the crypto market decline on Monday.&nbsp;<stembedurl>https://stocktwits.com/Ed_83/message/634705139</stembedurl><blockquote>“Crypto suffered its largest ever liquidation event on October 10th, and open interest on ETH (per coinalyze.net fell -45% in the past 8 weeks (the largest ever decline in the history of ETH).”-Thomas "Tom" Lee of Fundstrat, Chairman, BitMine</blockquote>“This reset is healthy and sets the stage for price and fundamentals to eventually converge,” he said.&nbsp;BitMine Immersion stock has gained over 442% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bynd-stock-plummets-13-today-what-s-driving-the-decline/cL2NIygR3z8">BYND Stock Plummets 13% Today: What’s Driving The Decline?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Bitmine Immersion Technologies logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did BMNR Stock Fall 7% Today?

BitMine’s ETH assets alone account for about 2.8% of the total Ethereum supply. 

BitMine Immersion’s combined assets declined to $13.7 billion from $14.2 billion as of October 27.


<ul class="summary-bullets"><li>It is now unclear when the company would apply for approval of the gene therapy, it said.</li><li>uniQure, however, added that it intends to communicate with the FDA to determine a path forward toward approval of the therapy.&nbsp;</li><li>uniQure CEO termed the meeting outcome “unexpected.” &nbsp;</li></ul>uniQure N.V. (QURE) no longer believes that the U.S. Food and Drug Administration considers data from an early-to mid-stage trial of its investigational gene therapy for Huntington’s disease sufficient for approval, the company said on Monday.The company recently met with the agency, and although the minutes of the meeting have not been received, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179114/0/en/uniQure-Provides-Regulatory-Update-on-AMT-130-for-Huntington-s-Disease.html">believes</a> that the FDA no longer considers the data from the AMT-130 trial adequate to provide primary evidence in support of an application for approval.As a result, it is now unclear when the company would apply for approval of the gene therapy, it said. uniQure, however, added that it intends to communicate with the FDA to determine a path forward toward approval of the therapy.<h2 class="st-heading-2">CEO Reacts</h2>uniQure CEO termed the meeting outcome “unexpected.”“We are surprised by the FDA’s feedback at the recent pre-BLA meeting, which is a drastic change from the guidance the FDA provided in November 2024 that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway,” CEO Matt Kapusta said.The company also stated that it intends to engage in further communications with other regulatory agencies while working with the FDA.<h2 class="st-heading-2">Expert Take</h2>Stifel analyst Annabel Samimy said that the news regarding the FDA's reversal on the approvability of uniQure's AMT-130 based on early to mid-stage trial data on the surface injects another layer of uncertainty into the workings of the FDA and their receptivity to gene therapy, more specifically.The analyst, however, does not expect this to impact Regenxbio’s (RGNX) rare disease programs. Meanwhile, Raymond James added that it does not expect the meeting outcome to impact Biohaven (BHVN) either.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>QURE stock traded 55% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QURE">QURE stock</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.QURE stock is up 72% this year and approximately 445% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-stock-soars-after-company-ups-guidance-for-multiple-sclerosis-drug/cL2NEPSR3zl">TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

uniQure Stock Tumbled 55% Today: What’s The FDA Angle?

The company recently met with the FDA and believes that the agency no longer considers the data from an early-to-mid-stage trial of its investigational gene therapy sufficient for approval.

<ul class="summary-bullets"><li>Adeia Inc. slashed its revenue and net income outlook for FY2025.</li><li>The company filed patent infringement lawsuits against AMD.</li><li>The lawsuit pertains to the alleged infringement of 10 semiconductor patents.</li></ul>&nbsp;Shares of Adeia Inc. (ADEA) slumped nearly 24% in early trade on Monday, and are on track to record their sharpest intraday decline in over five years. The stock has fallen below its 200-day moving average (DMA) on Monday for the first time since early August.The company has slashed its FY2025 revenue and net income outlook, citing the possibility of not proceeding with a license agreement with AMD. The company has revised its revenue expectations to $360 million to $380 million, down from its earlier guidance of $390 million to $430 million. Net income projections have been reduced to $52.4 million to $71.6 million, compared to the previous range of $85.1 million to $86.5 million.“While we still have paths to achieve our original revenue guidance range for the year, we have taken a prudent approach and adjusted our 2025 full-year guidance primarily to reflect that the license agreement we had been pursuing with AMD is now unlikely to close in the fourth quarter of this year as we had previously expected,” said Paul E. Davis, CEO of Adeia.While Adeia’s Q3 revenue improved marginally to $87.3 million, net income more than halved to $8.8 million.<h2 class="st-heading-2">Lawsuit Against AMD</h2>Earlier on Monday, Adeia filed patent infringement lawsuits against Advanced Micro Devices, Inc. (AMD) in the U.S. District Court for the Western District of Texas. The company claims that AMD has violated 10 of its semiconductor patents, including seven related to hybrid bonding technology and three related to advanced process node technology.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the significant intraday decline, retail sentiment on Stocktwits&nbsp;remained within the ‘bullish’ territory over the past day while message volume rose to ‘high’ level from ‘neutral’.&nbsp;<figure class="image"><img style="aspect-ratio:915/93;" src="https://news.stocktwits-cdn.com/ADEA_png_c36ee02bdd.webp" alt="ADEA.png" width="915" height="93"><figcaption>ADEA's Sentiment meter and Message Volumes at 10:45 a.m. ET on November 3, 2025 | Source: Stocktwits</figcaption></figure>The shares have fallen around 4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

Adeia’s Stock Crashed 24% Today To Dip Below 200-DMA For First Time Since Early August: What’s Driving The Decline?

The stock is on track to record its biggest intraday decline in over five years.

<ul class="summary-bullets"><li>On October 24, the company released preliminary financial results for the third quarter (Q3), stating that it anticipated revenue to reach around $70 million.</li><li>The company anticipates recording a material non-cash impairment charge for certain long-lived assets.</li><li>Beyond Meat will now release its Q3 earnings on November 11.&nbsp;</li></ul>Beyond Meat, Inc. (BYND) has announced a delay in releasing its third-quarter (Q3) financial results, with the company now planning to share the report after market close on Tuesday, November 11.&nbsp;The Q3 earnings had previously&nbsp;been scheduled to be released on November 4.&nbsp;<h2 class="st-heading-2">Preliminary Figures And Impairment Charges</h2>On October 24, the company released preliminary financial results for Q3, stating that it anticipated revenue to reach around $70 million, aligning with its previously shared guidance range of $68 million to $73 million.Despite the stable revenue, Beyond Meat faced pressures on its profitability. The company expects its gross margin for the quarter to fall between 10% and 11%, taking into account approximately $1.7 million in costs associated with the suspension and major scale-back of operations in China.&nbsp;Excluding the charges, the gross margin is estimated between 12% and 13%.&nbsp;<a href="https://stocktwits.com/symbol/BYND">Beyond Meat’s stock</a> traded over 13% lower on Monday, after the morning bell.&nbsp;The company also anticipates recording a material non-cash impairment charge for certain long-lived assets. A preliminary assessment under ASC 360 indicated that the carrying value of some assets is not fully recoverable from projected future cash flows. Although the charge is expected to be significant, management has yet to finalize its amount.As a result, the numbers may shift materially when the final audited figures are released.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory. Message volume shifted to ‘normal’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:925/109;" src="https://news.stocktwits-cdn.com/Screenshot_2025_11_03_093817_png_7a7191db94.webp" alt="BYND’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Nov. 3, 2025 | Source: Stocktwits" width="925" height="109"><figcaption>BYND’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Nov. 3, 2025 | Source: Stocktwits</figcaption></figure>The ticker gained significant buzz on Stocktwits. A bullish user sounded positive despite the delayed earnings.<stembedurl>https://stocktwits.com/Pink05/message/634672441</stembedurl>Beyond Meat’s stock has lost 61% in 2025 and over 76% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-allows-microsoft-to-export-nvidia-chips-to-uae/cL2N5QkR3zg">Microsoft Gets US Approval To Export Nvidia Chips In $15.2B UAE AI Push</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Beyond Meat's Beyond Burgers is shown on February 29, 2024 in Chicago, Illinois. (Photo illustration by Scott Olson/Getty Images)

BYND Stock Plummets 13% Today: What’s Driving The Decline?

On October 24, the company released preliminary financial results for the third quarter (Q3), stating that it anticipated revenue to reach around $70 million.

The company anticipates recording a material non-cash impairment charge for certain long-lived assets.


<ul class="summary-bullets"><li>Unit ReElement Technologies signs a $1.4 billion deal with the U.S. Department of War and Vulcan Elements</li><li>Goal is to establish a fully integrated domestic supply chain for rare earth magnets</li><li>OSC will provide two loans matched by private capital - $620 million to Vulcan Elements and $80 million to ReElement Technologies</li></ul>&nbsp;Shares of American Resources Corporation (AREC)&nbsp;gained 16% in early trade on Monday&nbsp;after its unit ReElement Technologies Corporation signed a $1.4 billion deal with the U.S. Department of War’s Office of Strategic Capital (OSC) and Vulcan Elements.The goal of the deal is to establish a fully integrated domestic supply chain for rare earth magnets. The agreement expands ReElement’s collaboration with Vulcan and enhances federal support for strengthening the U.S. critical minerals sector.In August, Vulcan Elements and ReElement Technologies signed a commercial-scale offtake agreement for light and heavy rare earth oxides.<h2 class="st-heading-2">What Does The Deal Entail?</h2>Under the arrangement, the OSC will provide two loans, matched by private capital, totaling $700 million: $620 million to Vulcan Elements and $80 million to ReElement Technologies. The funding will boost the companies’ capabilities in rare earth element separation, metallization, and magnet manufacturing, supporting a production capacity of up to 10,000 metric tonnes of Neodymium Iron Boron (NdFeB) magnets.This initiative is expected to narrow the U.S. supply gap in rare earth magnet production, a key material for defense, renewable energy, and electric vehicle industries.As part of the agreement, the U.S. Department of War will also receive warrants in ReElement Technologies. The loans are funded through a federal initiative enacted in July 2025, which authorizes up to $100 billion in lending to advance domestic production of critical minerals and related technologies.<h2 class="st-heading-2">The Rare Earth Standoff</h2>Rare earth elements are a key factor in the ongoing “tariff wars” between the U.S. and China. The dragon controls roughly 70% of global rare earth mining and nearly 90% of processing capacity, giving it substantial influence over the sector. Any disruption in the supply chain causes significant damage to key manufacturing sectors.However, after a crucial meeting between Chinese Premier Xi Jinping and U.S. President Donald Trump last week, China announced plans to pause its restrictions on rare-earth exports.Despite the development, the White House has stepped up its efforts over the past months to increase domestic production of critical minerals. The U.S. has taken stakes in companies such as Lithium Americas, MP Materials, Critical Metals, and Trilogy Metals. The White House has also stated that it is in talks with many other companies over potential stakes.<h2 class="st-heading-2">What Are Retail Investors Saying?</h2>Retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier.<figure class="image"><img style="aspect-ratio:924/88;" src="https://news.stocktwits-cdn.com/AREC_png_93c054dfe3.webp" alt="AREC.png" width="924" height="88"><figcaption>AREC's Sentiment Meter and Message Volumes at 09:35 a.m. ET on Nvember 3, 2025 | Source: Stocktwits</figcaption></figure>One user believes <a href="https://stocktwits.com/symbol/AREC">AREC's stock</a> could climb to $50.<stembedurl>https://stocktwits.com/Dreaming_big/message/634674207</stembedurl>The stock has more than quadrupled in value so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

AREC Stock Soars On $1.4 Billion Rare Earth Partnership With US Government

As part of the agreement, the U.S. Department of War will also receive warrants in ReElement Technologies

<ul class="summary-bullets"><li>OpenAI will immediately start utilizing AWS compute as part of this partnership, with all capacity targeted for deployment by the end of 2026, and the ability to expand further into 2027 and beyond.</li><li>The companies stated that this agreement would enable them to expand to tens of millions of CPUs, allowing for rapid scaling of agentic workloads.</li><li>Last week, Amazon raised its 2025 capital expenditure estimate to $125 billion, up from the prior expectation of $118 billion, as it scales up its AI investment.</li></ul>Amazon Web Services (AWS) and OpenAI announced on Monday a multi-year, strategic partnership that provides AWS’s infrastructure to run and scale the ChatGPT maker’s core artificial intelligence (AI) workloads, effective immediately.&nbsp;The companies said that under the $38 billion agreement, which is expected to continue growing over the next seven years, OpenAI is accessing AWS compute, comprising hundreds of thousands of state-of-the-art Nvidia (NVDA) Graphic Processing Units (GPUs).This would help with the ability to expand to tens of millions of CPUs to rapidly scale agentic workloads. “Clustering the NVIDIA GPUs—both GB200s and GB300s—via Amazon EC2 UltraServers on the same network enables low-latency performance across interconnected systems, allowing OpenAI to efficiently run workloads with optimal performance,” Amazon said.Retail sentiment on Amazon remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits. Shares of the company were up nearly 5% in early trading.<h2 class="st-heading-2">AI Scaling And Partnerships</h2>Amazon.com (AMZN) said that the swift scaling of AI technology has now created “unprecedented demand” for computing power. The company stated that as frontier model providers seek to elevate their models to new heights of intelligence, they are increasingly turning to AWS.According to the companies, OpenAI will immediately start utilizing AWS compute as part of this partnership, with all capacity targeted for deployment by the end of 2026, and the ability to expand further into 2027 and beyond.Amazon said that the clusters are designed to support various workloads, from serving inference for ChatGPT to training next-generation models, with the flexibility to adapt to OpenAI's evolving needs.Last week, Amazon raised its 2025 capital expenditure estimate to $125 billion, up from the prior expectation of $118 billion, as it scales up its AI investment.<h2 class="st-heading-2">Executive Take On The Partnership</h2>AWS CEO Matt Garman said that as OpenAI continues to push its boundaries, AWS’ infrastructure will serve as a “backbone for their AI ambitions.”“Scaling frontier AI requires massive, reliable compute," said OpenAI co-founder and CEO Sam Altman. “Our partnership with AWS strengthens the broad compute ecosystem that will power this next era and bring advanced AI to everyone,” he added.<a href="https://stocktwits.com/symbol/AMZN">Shares of Amazon</a> have gained over 17% this year and have jumped nearly 32% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/mongo-db-names-cloudflare-s-chirantan-desai-as-new-ceo-stock-jumps-9/cL2N4YOR3zm">MongoDB Names Cloudflare’s Chirantan Desai As New CEO, Stock Jumps 9%</a>

OpenAI CEO Sam Altman with a smartphone displaying OpenAI logo. The ChatGPT operator is expected to announce a slew of product updates at its developer conference, DevDay 2025, on Monday. (Photo by Didem Mente/Anadolu via Getty Images)

OpenAI Partners With AWS In $38B Cloud Pact To Scale AI Workloads Using Nvidia GPUs

The companies stated that this agreement would enable them to expand to tens of millions of CPUs, allowing for rapid scaling of agentic workloads.

<ul class="summary-bullets"><li>Desai was most recently the President of Product and Engineering at Cloudflare, where he drove product strategy and execution during a period of strong revenue growth.</li><li>MongoDB noted that Ittycheria will remain on the company’s board and serve as an advisor to Desai, helping with the execution of the company's long-term strategy.</li><li>The company stated that, based on preliminary results, it expects to exceed the high end of the provided third-quarter forecast for revenue and profit, driven by continued strength in Atlas.&nbsp;</li></ul>MongoDB (MDB) said on Monday that it has named Cloudflare executive Chirantan Desai as its new Chief Executive Officer, effective November 10, succeeding long-time head Dev Ittycheria.Shares of MongoDB jumped nearly 4% in early trading. The company said that Ittycheria has been leading MongoDB for 11 years and has announced his decision to retire from a full-time operating role.MongoDB noted that Ittycheria will remain on the company’s board and serve as an advisor to Desai, helping with the execution of the company's long-term strategy.Retail sentiment on MongoDB remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Desai’s Cloud And AI Experience</h2>The company stated that Desai joins MongoDB with over 25 years of experience in pioneering technology solutions for cloud infrastructure, enterprise software, cybersecurity, AI, and large-scale SaaS platforms.He was most recently the President of Product and Engineering at Cloudflare, where he drove product strategy and execution during a period of strong revenue growth and stock performance for the company, according to MongoDB.Prior to joining Cloudflare, Desai served as President and Chief Operating Officer at ServiceNow, where he helped the company scale organically from $1.5 billion to over $10 billion in annualized revenue.“His deep understanding and early deployment of AI in the enterprise will be invaluable as MongoDB continues to deliver for its customers,” said Tom Killalea, Chairman of the MongoDB Board of Directors.<h2 class="st-heading-2">MongoDB’s Q3 Outlook</h2>The company stated that, based on preliminary results, it expects to exceed the high end of the provided third-quarter forecast for revenue and profit, driven by continued strength in Atlas.&nbsp;MongoDB had forecast third-quarter revenue of $587 million to $592 million in August and adjusted earnings per share of $0.76 to $0.79.<a href="https://stocktwits.com/symbol/MDB">Shares of MongoDB</a> have gained 60% this year and have risen over 39% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cifr-stock-surges-on-5-5-billion-15-year-lease-agreement-with-aws/cL2N5WfR3zW">CIFR Stock Surges On $5.5 Billion, 15-Year Lease Agreement With AWS</a>

In this photo illustration, a hand holds a smartphone displaying the logo of MongoDB Inc.

MongoDB Names Cloudflare’s Chirantan Desai As New CEO, Stock Jumps 9%

MongoDB noted that Ittycheria will remain on the company’s board and serve as an advisor to Desai, helping with the execution of the company's long-term strategy.

TG Therapeutics, Inc. (TGTX) on Monday raised the full-year revenue guidance for its multiple sclerosis drug, Briumvi, to reflect strong market demand.The company now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-reports-third-quarter-2025-financial-results-and">expects</a> full-year Briumvi U.S. net revenue to be approximately $585 million, up from its previous guidance of $570 million to $575 million. The company also subsequently raised its full-year overall revenue guidance to $600 million, up from its previous forecast of $585 million.<h2 class="st-heading-2">TG’s Blockbuster Drug</h2>Briumvi is a prescription medication used to treat adults with relapsing forms of multiple sclerosis (MS). Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the myelin sheath, the protective covering of nerve cells in the brain and spinal cord. This damage disrupts nerve signals, leading to a wide range of neurological symptoms, including numbness, vision problems, and difficulties with balance, coordination, and walking.“As we move through the fourth quarter, we remain focused on expanding patient awareness, advancing enrollment into our ongoing clinical trials, and driving growth and long-term value for our shareholders,” CEO Michael S. Weiss said on Monday.The company is currently undertaking two late-stage programs of Briumvi, evaluating subcutaneous and intravenous formulations of the drug.In the third quarter, the company reported total revenue of $161.7 million, of which Briumvi U.S. revenue accounted for about 95%. This also beat an analyst estimate of $152.17 million, according to data from Fiscal AI.Net income for the quarter came at $390.9 million, compared to $3.9 million in the corresponding quarter of 2024. The company ended the quarter with cash, cash equivalents, and investment securities of $178.3 million, which it expects to be sufficient to fund its business, when coupled with Briumvi revenues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/TGTX">Shares of TGTX</a> jumped 4% in the premarket session at the time of writing. On Stocktwits, retail sentiment around TGTX stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed within ‘high’ levels.TGTX stock is up 16% this year and approximately 43% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-files-second-lawsuit-against-metsera-novo-nordisk/cL2N3Z5R3zi">The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug

The company now expects full-year Briumvi U.S. net revenue to be approximately $585 million, up from its previous guidance of $570 million to $575 million.

<ul class="summary-bullets"><li>Shares of New Gold surged over 10%, while Coeur Mining’s stock was down 5.8%</li><li>Coeur will own 62% of the company while New Gold shareholders will hold the remaining 38%.</li><li>The combined entity will operate seven mines</li></ul>&nbsp;Shares of New Gold Inc. (NGD) surged over 10% in premarket trade on Monday, after the company announced that Coeur Mining, Inc. (CDE) will acquire the company for around $7 billion.<a href="https://stocktwits.com/symbol/CDE">Coeur Mining’s shares</a> were down 5.8% at $16.6.Under the terms of the agreement, New Gold shareholders will receive 0.4959 Coeur shares for each New Gold share, representing a 16% premium to New Gold’s closing price on October 31. The merger will create a North America-focused precious metals producer with an estimated market capitalization of $20 billion.&nbsp;Coeur will own 62% of the company while New Gold shareholders will hold the remaining 38%.<h2 class="st-heading-2">Forming A $20 Billion Powerhouse</h2>The new company will operate seven mines, producing around 1.25 million gold-equivalent ounces (GEO) annually, including 900,000 ounces of gold and 20 million ounces of silver.The expected EBITDA for 2026 is $3 billion, and the free cash flow of $2 billion will more than double Coeur’s current projections, strengthening its balance sheet and supporting a potential investment-grade rating. The deal is accretive to all key financial metrics.&nbsp;The&nbsp;stronger&nbsp;financial position will&nbsp;enable&nbsp;increased investments in high-return growth projects, including New Afton’s K-Zone, Rainy River expansion, and exploration across Coeur’s U.S., Mexico, and Canadian assets.Upon completion, Coeur CEO Mitchell J. Krebs will lead the combined company, with New Gold CEO Patrick Godin joining Coeur’s board. The transaction is expected to close in the first half of 2026.<h2 class="st-heading-2">Stocktwits Users Buoyant</h2><a href="https://stocktwits.com/symbol/NGD">NGD’s</a> retail investors on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a session earlier. Chatter was ‘extremely high’.<figure class="image"><img style="aspect-ratio:918/97;" src="https://news.stocktwits-cdn.com/NGD_png_242aaac100.webp" alt="NGD.png" width="918" height="97"><figcaption>NGD's Sentiment Meter and Message Volumes at 08:30 a.m. ET on November 3, 2025 | Source: Stocktwits</figcaption></figure>Despite the premarket declines, retail sentiment for CDE remained ‘bullish’.<figure class="image"><img style="aspect-ratio:922/99;" src="https://news.stocktwits-cdn.com/CDE_png_198064cf72.webp" alt="CDE.png" width="922" height="99"><figcaption>CDE's Sentiment Meter and Message Volumes at 08:30 a.m. ET on November 3, 2025 | Source: Stocktwits</figcaption></figure>Both stocks have seen significant buying interest so far in 2025, gaining around&nbsp;193%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Local inhabitants work in artisanal gold mining outdoors in Senegal

New Gold Stock Rises 10%, Retail Traders Turn Upbeat As Coeur Mining Announces $7B Acquisition

The expected EBITDA post-acquisition is $3 billion in 2026, with free cash flow of $2 billion

SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending due to a recently announced $9.7 billion AI cloud services deal with Microsoft, which includes access to NVIDIA GPUs and a 20% prepayment. The community is highly bullish, discussing potential price targets and the significance of this deal in establishing IREN as a major player in AI infrastructure. Some investors believe that AI revenue will soon drive the stock, decoupling it from Bitcoin's volatility.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a sharp sell-off possibly linked to news of a lawsuit against a former FDA official, which is creating uncertainty around the stock. The community is discussing the implications of this news, potential manipulation, and the company's upcoming earnings report. Some investors speculate about a buyout or partnership, while others express concern about the company's leadership and its impact on the stock's performance.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as the community rallies around the tokenization of Satoshi Nakamoto, viewing it as more than just a meme, but as a representation of crypto culture and financial freedom. Discussions highlight the token's potential to become a significant asset, drawing parallels to Bitcoin's cultural impact and long-term value. The community emphasizes the narrative's timelessness and the ongoing initiatives surrounding the token.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as the community discusses its potential for growth, particularly regarding its QNX technology and partnerships with major tech companies. Some investors believe the current stock price undervalues the company's assets and future prospects, while others point to potential market manipulation and short-selling tactics affecting the stock's performance. The potential impact of government support and expansion in Asian markets are also being closely watched.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences is gaining attention as traders discuss its potential for a significant price movement, drawing comparisons to other low-float stocks that have experienced substantial short squeezes. Community members are actively watching the stock, citing its low float and speculating about news catalysts. Some believe a coordinated effort from retail investors could lead to a squeeze comparable to previous high-profile situations.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending as investors anticipate its earnings report, with debates raging about whether the stock is overvalued or poised for further gains. Bullish sentiment is fueled by Wedbush raising its price target and the company's involvement in the AI revolution, while bears cite its high P/E ratio. The community is closely watching for contract updates and guidance.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to a significant stock movement following an unexpected shift in the FDA's stance on data requirements for its Huntington's disease therapy, AMT-130. The community is actively discussing the potential implications of this regulatory setback, with some speculating about a possible reversal of the decision or a buyout, while others assess the impact on the broader biotech sector. Discussions include the company's financial strategies, the possibility of a dead cat bounce, and the overall volatility and risk associated with biotech investments.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is trending following positive clinical data from its TERN-701 trial, selected for oral presentation at an upcoming hematology conference, driving speculation of a potential buyout. Community members are weighing the bullish data against a recent $300M shelf registration, debating short-squeeze potential versus dilution risks. The focus shifts to TERN's oncology program after the discontinuation of their GLP-1 candidate, with some viewing it as a streamlined path to acquisition.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as traders discuss whether it's setting up for a similar breakout to Amazon, focusing on accumulation patterns and potential FOMO. Some investors are frustrated with the stock's recent performance despite positive earnings, while others see it as an undervalued long-term play, especially with upcoming events like the World Cup and Olympics.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

NFLX is trending as investors discuss potential catalysts after a recent dip, including speculation around a stock split and potential acquisition of Warner Bros. Discovery assets. The community is weighing the impact of these factors against concerns about broader market conditions and specific challenges facing the company, like woke agenda pushing and subscriber losses. Some traders are seeing a buying opportunity, while others remain cautious.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


News